Search results for Ascrinvacumab

Ascrinvacumab, Abbexa, abx831350

Ascrinvacumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting ACVRL1/SKR3/TGF-B/TSR-I, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Ascrinvacumab has been used in trials studying the treatment and basic science of Neoplasms, Advanced Solid Tumors, Carcinoma, Hepatocellular, and Malignant Pleural Mesothelioma.

Ascrinvacumab ELISA Kit, ProteoGenix, KPTX226

Description of Ascrinvacumab ELISA Kit Introduction to Ascrinvacumab ELISA Kit Ascrinvacumab ELISA Kit is a highly sensitive and specific diagnostic tool used for the detection and quantification of Ascrinvacumab, a novel therapeutic antibody. This kit is designed for use in research and clinical laboratories, and provides a reliable and efficient method for measuring the levels of Ascrinvacumab in various biological samples. Structure of Ascrinvacumab Ascrinvacumab is a monoclonal antibody that specifically targets the protein Ascrinvacuolin, which is overexpressed in certain types of cancer cells. It is a fully humanized IgG1 antibody, meaning that it is derived from human cells and has minimal immunogenicity, making it suitable for therapeutic use in humans. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The variable regions of the antibody, which are responsible for binding to the target protein, are located at the tips of the heavy and light chains. These regions are highly specific and have been engineered to have a high affinity for Ascrinvacuolin. Activity of Ascrinvacumab Ascrinvacumab works by binding to Ascrinvacuolin on the surface of cancer cells, thereby blocking its function. Ascrinvacuolin is a key player in the growth and survival of cancer cells, and by inhibiting its activity, Ascrinvacumab effectively slows down or even halts the progression of the disease. In addition, Ascrinvacumab also activates the immune system to recognize and attack cancer cells that express Ascrinvacuolin. This mechanism, known as antibody-dependent cell-mediated cytotoxicity (ADCC), further enhances the therapeutic effects of Ascrinvacumab. Application of Ascrinvacumab ELISA Kit The Ascrinvacumab ELISA Kit is a valuable tool for both research and clinical applications. In research, it can be used to measure the levels of Ascrinvacumab in various biological samples, such as serum, plasma, and tissue lysates. This allows researchers to monitor the pharmacokinetics of Ascrinvacumab, as well as its distribution and clearance from the body. In clinical settings, the Ascrinvacumab ELISA Kit can be used for diagnostic purposes, as well as for monitoring the response to treatment. By measuring the levels of Ascrinvacumab in patient samples, clinicians can determine the efficacy of the therapy and make informed decisions about the course of treatment. Furthermore, the Ascrinvacumab ELISA Kit can also be used for quality control purposes during the production of Ascrinvacumab. By ensuring the consistency and potency of each batch of the therapeutic antibody, this kit plays a crucial role in maintaining the safety and efficacy of the drug. Conclusion In summary, the Ascrinvacumab ELISA Kit is a powerful tool for the detection and quantification of Ascrinvacumab, a novel therapeutic antibody. Its high sensitivity and specificity make it an ideal choice for both research and clinical applications. With the increasing use of Ascrinvacumab in cancer treatment, this kit will continue to play a vital role in monitoring and improving patient outcomes.

Ascrinvacumab ELISA Kit, Abbexa, abx395115

Ascrinvacumab ELISA Kit is a quantitative ELISA kit for detection of Ascrinvacumab.Ascrinvacumab, also known as PF-03446962 or anti-hALK1 antibody, is a human immunoglobulin G (IgG) 2 monoclonal antibody which can be used as therapeutic antibody drug for the treatment of many tumors. It has been found that the clinical trials of ascrinvacumab has been developed in cancers including advanced solid tumors, urothelial cell carcinoma, hepatocellular carcinoma, and mesothelioma. Ascrinvacumab can binding to ACVRL1 by recognizing the extracellular domain of ACVRL1. ACVRL1, also called activin receptor-like kinase 1 (ALK1), is a transforming growth factor β (TGF-β) type I receptor. Ascrinvacumab is a fully human monoclonal antibody generated by immunizing the IgG 2 transgenic XenoMouse. In a human/mouse chimera tumor model, ascrinvacumab decreased human vessel density and improved antitumor efficacy when combined with bevacizumab (anti-VEGF). It suggests that ascrinvacumab therapy may be complementary to anti-VEGF in cancer intervention. As early as 2012, researchers had investigated the effects of ascrinvacumab on endothelial cell function. And the results showed that ascrinvacumab do interferes with the endothelial cell sprouting induced by Bone Morphogenetic Protein 9 (BMP9). A phase 2 trial study of ascrinvacumab in pre-treated patients with urothelial cancer had been reported in 2014. In addition, its treatment results of advanced solid tumors, hepatocellular carcinoma, and advanced malignant pleural mesothelioma also had been reported in 2016. In addition to advanced malignant pleural mesothelioma, ascrinvacumab shows the value of continuing treatment evaluation in the other two diseases.

Ascrinvacumab Biosimilar - Research Grade, ichor.bio, ICH5355